Observational studyJournal of epidemiology and global health2026
Hepatitis C Virus Infection at the Start of Hemodialysis and During Early Follow-up: Evidence from Two Dialysis Centers.
Observational study in Journal of epidemiology and global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) remains a concern in patients undergoing maintenance hemodialysis due to repeated blood exposure and prolonged contact with dialysis environments. Although direct-acting antivirals have reduced HCV burden in many settings, uncertainty persists regarding early infection dynamics at dialysis initiation and during initial follow-up.
methodsThis observational study was conducted in two hemodialysis facilities in northern Iran (2022-2023). All adult patients receiving maintenance hemodialysis were included using a census-based approach. HCV status was assessed by anti-HCV antibody testing at dialysis initiation and repeated after three months as part of routine surveillance. Demographic and clinical variables, including dialysis duration and transfusion history, were extracted from medical records. Analyses focused on prevalence and associations with clinical characteristics.
resultsAmong 470 patients, six (1.28%) were anti-HCV positive at dialysis initiation. After three months, no new cases were identified; overall prevalence remained unchanged. No significant associations were observed between HCV status and demographic variables, transfusion history, or comorbidities. In contrast, dialysis duration showed a clear association with HCV positivity. Patients with more than ten years of dialysis had markedly higher prevalence than those with shorter durations (P < 0.001).
conclusionsIn this cohort, HCV prevalence at the start of dialysis was low and remained stable during short-term follow-up. Longer dialysis duration was the only factor associated with HCV positivity, supporting its role as a cumulative exposure marker. These findings emphasize the importance of sustained infection-control practices and continued surveillance, even in low-prevalence settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.